List of Excipients in Branded Drug PRAVACHOL

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
ER Squibb & Sons LLC	PRAVACHOL	pravastatin sodium	0003-5178	CELLULOSE, MICROCRYSTALLINE
ER Squibb & Sons LLC	PRAVACHOL	pravastatin sodium	0003-5178	CROSCARMELLOSE SODIUM
ER Squibb & Sons LLC	PRAVACHOL	pravastatin sodium	0003-5178	FERRIC OXIDE YELLOW
ER Squibb & Sons LLC	PRAVACHOL	pravastatin sodium	0003-5178	LACTOSE
ER Squibb & Sons LLC	PRAVACHOL	pravastatin sodium	0003-5178	MAGNESIUM OXIDE
ER Squibb & Sons LLC	PRAVACHOL	pravastatin sodium	0003-5178	MAGNESIUM STEARATE
ER Squibb & Sons LLC	PRAVACHOL	pravastatin sodium	0003-5178	POVIDONE

Pravachol Excipient Strategy and Commercial Opportunities for Pravastatin Sodium

Last updated: August 28, 2026

Pravachol is the branded formulation of pravastatin sodium, an HMG-CoA reductase inhibitor used to reduce low-density lipoprotein cholesterol and cardiovascular risk. Its U.S. composition is technically conventional: immediate-release tablets using lactose, microcrystalline cellulose, croscarmellose sodium, povidone, magnesium oxide, magnesium stearate and talc, with strength-specific colorants. The commercial opportunity is therefore not protection of the legacy product. It is differentiated generic delivery, excipient substitution, patient-specific formulations, global registration efficiency and manufacturing cost reduction.

Pravastatin is a mature, off-patent small molecule. Generic competition is established, biosimilar risk is not relevant, and the original brand has limited strategic value unless a company can create a differentiated formulation or access an underserved market segment.

What excipients are used in Pravachol tablets?

Pravachol tablets use a conventional direct-compression or dry-granulation excipient system built around a diluent, disintegrant, binder, lubricant and glidant.

Pravachol inactive ingredients

The U.S. prescribing information identifies the following inactive ingredients across the tablet strengths:

Excipient	Primary formulation function	Commercial relevance
Lactose	Filler and compression aid	Low cost, but relevant to lactose intolerance, labeling and supply continuity
Microcrystalline cellulose	Diluent, dry binder and compressibility enhancer	Supports robust tablet manufacture and hardness control
Croscarmellose sodium	Superdisintegrant	Drives rapid tablet breakup and immediate release
Povidone	Binder	Supports granule cohesion and content uniformity
Magnesium oxide	Alkaline excipient and formulation component	Can affect microenvironmental pH and chemical stability
Magnesium stearate	Lubricant	Controls ejection force but can retard dissolution if over-lubricated
Talc	Glidant and anti-adherent	Improves powder flow and manufacturing performance
Colorants	Product identification	May vary by strength and create regulatory change-control requirements

The product is an immediate-release oral tablet. Pravachol does not rely on a modified-release polymer, enteric coating, lipid vehicle or specialized delivery system in its conventional U.S. formulation. [1]

Why magnesium oxide matters in pravastatin formulation design

Magnesium oxide is a notable component because pravastatin sodium is a salt and formulation performance can be affected by pH, ionic environment, moisture and excipient compatibility. A developer seeking to replicate the product should evaluate:

• Assay and degradation under accelerated stability conditions.
• Dissolution across physiologically relevant pH conditions.
• Moisture uptake and tablet hardness.
• Compatibility with lactose and povidone.
• The effect of lubricant concentration and mixing time.
• Potential changes in impurity profiles after replacing magnesium oxide.

A substitution that improves manufacturability may still create a dissolution or stability risk. Comparative dissolution should be performed across all strengths rather than relying on the 40-mg tablet as a surrogate.

What formulations are protected by Pravachol?

The legacy Pravachol formulation is not a meaningful current exclusivity platform in the United States. Pravastatin sodium tablets are widely available as generic immediate-release products, and the original brand-related patent protection has expired.

Potentially protectable formulation concepts include:

1. Lactose-free pravastatin tablets.
2. Orally disintegrating tablets.
3. Sprinkle formulations for patients with swallowing difficulty.
4. Low-dose pediatric or geriatric dosage forms.
5. Taste-masked oral granules or mini-tablets.
6. Fixed-dose combinations with antihypertensive or antiplatelet agents.
7. Moisture-protected tablets for tropical markets.
8. Dose-flexible multiparticulate products.
9. Packaging systems that improve adherence or stability.
10. Formulations designed for patients with excipient sensitivities.

A new formulation would need a credible technical advantage. Simply replacing one filler with another is unlikely to create durable commercial differentiation unless the change produces a measurable clinical, stability, manufacturability or regulatory benefit.

Is the Pravachol formulation patentable today?

A new patent could potentially cover a novel composition, manufacturing process, dosage form or method of use. A patent on the historical Pravachol formulation would face serious novelty and obviousness problems because the product and its generic equivalents are long established.

The strongest remaining patent opportunities would usually require one of the following:

• A novel dosage form with improved administration.
• A clinically meaningful reduction in pill burden.
• A demonstrated stability advantage.
• A validated patient population with administration limitations.
• A non-obvious excipient combination producing an unexpected dissolution or bioavailability result.
• A manufacturing process that materially improves yield or impurity control.

A broad claim covering pravastatin sodium plus standard excipients would likely have limited defensibility.

When does Pravachol lose exclusivity?

Pravachol has already lost U.S. market exclusivity. The brand was approved by the FDA in 1991, and pravastatin sodium tablets are now supplied by multiple generic manufacturers. The product is no longer an attractive conventional small-molecule exclusivity asset. [1][2]

Regulatory asset	Status
U.S. new drug approval	Approved
Active ingredient	Pravastatin sodium
Dosage form	Immediate-release tablet
Strengths	10 mg, 20 mg, 40 mg and 80 mg
U.S. generic availability	Established
Biologic exclusivity	Not applicable
Biosimilar pathway	Not applicable
Brand exclusivity strategy	Expired
Current opportunity	Product differentiation and efficient generic supply

The exact commercial status of individual generic products depends on manufacturer, application, marketing status and supply conditions. FDA’s Orange Book and Drugs@FDA remain the controlling sources for application-level listings and approved product information. [2][3]

What is the Orange Book status of Pravachol?

Pravachol is an FDA-listed prescription drug with an established generic equivalent pathway. Orange Book analysis should distinguish between:

• The discontinued or legacy brand product.
• Active abbreviated new drug applications for pravastatin sodium tablets.
• Any historical patent listings associated with the reference product.
• Exclusivity codes that may appear for individual generic applications.

A current product-level assessment should not treat the existence of a historical Pravachol listing as evidence of active patent protection. For a mature product such as pravastatin, the principal commercial questions are supply, pricing, manufacturing cost and formulation differentiation, not reference-product exclusivity.

Are there Paragraph IV challenges to Pravachol?

Paragraph IV litigation is not a central current risk category for Pravachol because generic pravastatin sodium tablets are already marketed. Historical generic entry would have occurred through the ANDA process, with any patent certifications and associated litigation tied to the patents listed at the time of filing.

The more relevant legal risks today are:

• Patent disputes over a newly differentiated pravastatin formulation.
• Trade-secret disputes involving manufacturing processes.
• Trademark and trade-dress disputes involving Pravachol branding.
• ANDA litigation involving a later patent filed on a reformulated product.
• Regulatory disputes over bioequivalence or product-specific guidance.

A company developing a new pravastatin dosage form should conduct a freedom-to-operate review against formulation, process, combination-product and use patents rather than focus only on historical Pravachol patents.

What commercial opportunities exist for Pravachol excipients?

The strongest opportunities are in formulation redesign, not in copying the existing excipient list.

Lactose-free pravastatin tablets

A lactose-free formulation could target patients who avoid lactose or manufacturers seeking simplified excipient declarations. Microcrystalline cellulose, mannitol, dibasic calcium phosphate or spray-dried starch may be considered as alternative fillers.

The main development risks are tablet friability, dissolution changes, taste and supplier qualification. A lactose-free product would need to show that the excipient substitution does not alter bioequivalence or product quality.

Orally disintegrating pravastatin

An orally disintegrating tablet could target older adults and patients with dysphagia. Mannitol-based systems, crospovidone or co-processed excipients could improve mouthfeel and disintegration.

Pravastatin’s relatively modest dose strength supports feasibility, but taste masking and moisture protection may determine commercial viability. A formulation that disintegrates rapidly but has poor palatability may have little market value.

Sprinkle or multiparticulate dosage forms

Mini-tablets or granules could support administration to patients who cannot swallow conventional tablets. This approach may be useful in long-term-care, geriatric and home-care settings.

The key technical issues are:

• Uniform dose delivery.
• Protection from food interactions.
• Particle segregation.
• Taste masking.
• Stability after opening.
• Compatibility with soft food or liquids.

This is a potential 505(b)(2) or differentiated generic strategy depending on the product design and regulatory pathway. [4]

Pediatric formulation

Pravastatin use in pediatric populations is narrower than adult dyslipidemia treatment. A pediatric formulation would require a defined clinical and regulatory strategy, age-appropriate dosing and acceptable palatability.

The opportunity is more likely to arise from a hospital or specialty product than from a mass-market generic tablet. Regulatory value would depend on the intended population and clinical evidence rather than excipient novelty alone.

Fixed-dose combinations

A pravastatin combination with an antihypertensive, antiplatelet agent or other cardiovascular therapy could reduce pill burden. The commercial logic is strongest in markets where cardiovascular polypharmacy is common and combination products have reimbursement support.

Combination products create additional barriers:

• Dose-ratio constraints.
• Drug-drug stability.
• Distinct dissolution profiles.
• Clinical bridging requirements.
• Labeling and safety attribution.
• Separate patent estates for each active ingredient.

The excipient strategy must support both actives without compromising stability or bioavailability.

How strong is the patent estate for pravastatin formulations?

The legacy patent estate is weak as a barrier to standard generic tablets but can still be relevant as prior art in a new formulation program.

Asset category	Current barrier strength	Strategic implication
Original pravastatin compound patents	Low	Expired or commercially exhausted
Standard immediate-release tablet	Low	Highly commoditized
Conventional excipient substitutions	Low to moderate	Patentability depends on unexpected results
Orally disintegrating tablet	Moderate	Stronger if supported by performance data
Multiparticulate or sprinkle product	Moderate	Potential differentiation in dysphagia markets
Fixed-dose combination	Moderate to high	Depends on combination and remaining partner patents
Manufacturing process	Moderate	May protect cost or quality advantages
Packaging and moisture control	Low to moderate	Usually supports operations rather than market exclusivity

A formulation patent should be built around measurable performance. Claims limited to a list of routine excipients are less valuable than claims tied to dissolution, stability, disintegration, impurity control or a defined manufacturing parameter.

What FDA regulatory pathway applies to a new pravastatin product?

A conventional tablet that is pharmaceutically equivalent and bioequivalent to the reference product generally follows the ANDA pathway. A product with a new dosage form, route, indication or clinically meaningful formulation change may require a 505(b)(2) application. [4]

Product concept	Likely pathway
Conventional pravastatin tablet	ANDA
Lactose-free equivalent tablet	Usually ANDA if equivalence criteria are met
Orally disintegrating tablet	ANDA or 505(b)(2), depending on reference and claims
Sprinkle granules	Often 505(b)(2) or a product-specific generic strategy
New fixed-dose combination	505(b)(2) or NDA framework
New pediatric indication	NDA or 505(b)(2), depending on supporting evidence
Novel delivery system	Often 505(b)(2)

The regulatory value of an excipient change depends on whether it changes dosage form, administration, pharmacokinetics, labeling or clinical use. FDA’s inactive-ingredient database can support precedent analysis, but prior use does not guarantee approval for a specific formulation. [5]

Which companies are challenging or competing with Pravachol?

The competitive field consists primarily of generic manufacturers and private-label suppliers rather than branded challengers. Pravastatin sodium tablets have been marketed by multiple companies over time, including large generic manufacturers and contract suppliers.

Competition is based on:

• API sourcing.
• Manufacturing cost.
• FDA compliance history.
• Supply reliability.
• Wholesaler contracts.
• Strength availability.
• Reimbursement and formulary position.
• Ability to maintain inventory during shortages.

A reformulated product would compete with atorvastatin, simvastatin, rosuvastatin and other statins, not only with pravastatin generics. Pravastatin has a lower-intensity efficacy profile than high-potency statins, which limits the addressable market for premium reformulation unless the product solves a specific tolerability, administration or adherence problem.

What generic launch risks exist for a new pravastatin product?

A new launch faces low entry barriers for standard tablets but higher commercial barriers for differentiated products.

Generic launch scenarios

Scenario	Development profile	Commercial outlook
Standard 10-80 mg tablet	Low technical complexity	Price competition and limited margin
Lactose-free tablet	Moderate	Niche opportunity; limited exclusivity
Orally disintegrating tablet	Moderate to high	Potential premium if adherence benefit is demonstrated
Sprinkle formulation	High	Specialty and institutional opportunity
Fixed-dose combination	High	Larger differentiation but higher clinical and regulatory cost
Pediatric product	High	Narrower market, potentially stronger niche protection

The principal risks are low reimbursement, therapeutic substitution by atorvastatin or rosuvastatin, limited prescriber awareness and insufficient volume to offset development costs. A formulation with no clear patient or payer benefit is unlikely to sustain a premium.

What manufacturing and intellectual-property barriers matter?

The largest barriers are operational rather than patent-based.

Manufacturing barriers

Pravastatin product development should address:

• API particle-size control.
• Blend uniformity at low-dose strengths.
• Lubrication sensitivity.
• Moisture management.
• Tablet hardness and friability.
• Color consistency across strengths.
• Dissolution comparability.
• Cleaning validation for potent or low-dose materials.
• Supplier continuity for lactose, cellulose and superdisintegrants.

The 10-mg and 20-mg strengths may present greater content-uniformity risk than the 80-mg strength. Scale-up should assess each strength independently.

Intellectual-property barriers

A commercial freedom-to-operate review should include:

• Active formulation patents.
• Combination-product patents.
• Method-of-use claims.
• Manufacturing process patents.
• Drug-device claims for novel administration systems.
• Trademark restrictions involving Pravachol.
• Jurisdiction-specific patent rights outside the United States.

No biosimilar analysis is required because pravastatin is a chemically synthesized small molecule, not a biologic. [3]

What licensing deals and litigation affect Pravachol?

The historic brand was associated with Bristol-Myers Squibb, but Pravachol is no longer primarily a licensing or litigation-driven asset. Current licensing value would more likely arise from:

• A contract manufacturing arrangement.
• Regional commercialization rights.
• A differentiated delivery technology.
• A combination-product partnership.
• A specialty-market distribution agreement.

There is no commercial basis for assuming that a historic Pravachol license provides current exclusivity for a generic or reformulated product. Any transaction should separate rights to the active ingredient, finished dosage form, trademarks, regulatory dossier and manufacturing process.

What is the revenue exposure for a Pravachol reformulation?

Brand-level Pravachol revenue is not a reliable basis for valuing a new product because the market has shifted to low-priced generics. Revenue potential depends on the segment targeted:

Segment	Revenue quality	Main value driver
Standard generic tablets	Low margin	Volume and supply reliability
Institutional supply	Low to moderate margin	Contract access and continuity
Lactose-free product	Moderate niche value	Patient and pharmacy differentiation
Orally disintegrating product	Moderate	Adherence and dysphagia positioning
Sprinkle formulation	Moderate to high niche value	Long-term-care and specialty use
Fixed-dose combination	Potentially higher	Pill-burden reduction and reimbursement

A company should not underwrite a premium valuation from the Pravachol brand name alone. The investable asset is a new product profile with defensible claims, a defined patient need and a credible reimbursement pathway.

Key Takeaways

• Pravachol is pravastatin sodium in an immediate-release tablet.
• Its conventional excipients include lactose, microcrystalline cellulose, croscarmellose sodium, povidone, magnesium oxide, magnesium stearate and talc.
• Standard pravastatin tablets are off-patent and heavily commoditized.
• Biosimilar risk does not apply.
• The strongest commercial opportunities are lactose-free, orally disintegrating, sprinkle, pediatric and fixed-dose combination products.
• Routine excipient substitution has limited patent value unless supported by unexpected technical results.
• An ANDA is generally appropriate for an equivalent conventional tablet; differentiated dosage forms may require a 505(b)(2) strategy.
• Manufacturing reliability, API sourcing and reimbursement are more important current barriers than historical Pravachol patents.
• A new product should compete against atorvastatin, simvastatin and rosuvastatin, not only against pravastatin generics.
• The best commercial case is a targeted formulation solving dysphagia, adherence, excipient sensitivity or pill-burden problems.

FAQs

Can pravastatin tablets be made without lactose?

Yes. Lactose can potentially be replaced with microcrystalline cellulose, mannitol, dibasic calcium phosphate or another suitable diluent. The replacement must preserve content uniformity, hardness, friability, dissolution and stability.

Is magnesium oxide essential to the Pravachol formulation?

It is part of the labeled inactive-ingredient system for Pravachol tablets, but it is not necessarily indispensable to every pravastatin formulation. Removing or replacing it requires compatibility, stability and dissolution development.

Can an orally disintegrating pravastatin tablet receive new patent protection?

Potentially. Patent strength would depend on the specific composition, manufacturing process and demonstrated performance. A claim covering routine ODT excipients without unexpected results would face substantial prior-art risk.

Is pravastatin suitable for a pediatric liquid?

A liquid or suspension may be technically feasible, but the commercial and regulatory case depends on the target pediatric population, dosing requirements, palatability, stability and supporting clinical evidence.

Does a new pravastatin excipient combination avoid generic competition?

Not automatically. A novel excipient combination may support a formulation patent, but generic competition can still arise through alternative formulations, patent challenges or competing products that design around the claims.

References

1. U.S. Food and Drug Administration. (n.d.). Pravachol (pravastatin sodium) tablets prescribing information.
2. U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs.
4. U.S. Food and Drug Administration. (2023). Applications covered by section 505(b)(2).
5. U.S. Food and Drug Administration. (n.d.). Inactive ingredient database.